Thendor Therapeutics is an early-stage company developing peptide-based medicines intended to halt or reverse fibrosis and restore healthy tissue function across a range of fibrotic diseases. [1]
Its areas of focus include pulmonary fibrosis, urological fibrosis through its subsidiary Thenduro, systemic fibrotic diseases driven by shared biological pathways, and exposure-induced fibrosis. The company was co-founded by fibrosis researcher Carol Feghali-Bostwick, who serves as acting chief scientific officer, together with CEO Steven King and CFO Paul Lytle. [2]